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Aims: To evaluate real-world clinical outcomes for switching basal insulin analogues [insulin glargine (GLA) and insulin detemir (DET)] among US patients
with type 2 diabetes mellitus (T2DM).
Methods: Using the GE Centricity Electronic Medical Records database, this retrospective study examined two cohorts: cohort 1, comprising patients
previously on GLA and then either switching to DET (DET-S) or continuing with GLA (GLA-C); and cohort 2, comprising patients previously on DET and
then either switching to GLA (GLA-S) or continuing with DET (DET-C). Within each cohort, treatment groups were propensity-score-matched on baseline
characteristics. At 1-year follow-up, insulin treatment patterns, glycated haemoglobin (HbA1c) levels, hypoglycaemic events, weight and body mass index
(BMI) were evaluated.
Results: The analysis included 13 942 patients: cohort 1: n= 10 657 (DET-S, n= 1797 matched to GLA-C, n= 8860) and cohort 2: n= 3285 (GLA-S,
n= 858 matched to DET-C, n= 2427). Baseline characteristics were similar between the treatment groups in each cohort. At 1-year follow-up, in cohort
1, patients in the DET-S subgroup were significantly less persistent with treatment, more likely to use a rapid-acting insulin analogue, had higher HbA1c
values, lower HbA1c reductions and lower proportions of patients achieving HbA1c <7.0 or <8.0% compared with patients in the GLA-C subgroup, while
hypoglycaemia rates and BMI/weight values and change from baseline were similar in the two subgroups. In cohort 2, overall, there were contrasting
findings between patients in the GLA-S and those in the DET-C subgroup.
Conclusions: This study showed contrasting results when patients with T2DM switched between basal insulin analogues, although these preliminary
results may be subject to limitations in the analysis. Nevertheless, this study calls into question the therapeutic interchangeability of GLA and DET, and
this merits further investigation.
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Introduction
Type 2 diabetes mellitus (T2DM) is a progressive disease,
meaning that most patients will require the introduction of
insulin into their treatment regimen at some point during the
continuum of care [1]. To facilitate the transition to insulin,
numerous clinical and real-world studies have investigated the
efficacy and safety of initiating long-acting analogue insulins.
In clinical studies, both insulin glargine (GLA; Lantus®, Sanofi
US, Inc., Bridgewater, NJ, USA) and insulin detemir (DET;
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Levemir®, Novo Nordisk A/S, Bagsvaerd, Denmark) have
been shown to result in equivalent improvements in glycaemic
control with a low incidence of hypoglycaemia when used
as part of a basal-bolus regimen [2–4]. Although glycaemic
outcomes in such trials have been similar for these two basal
analogue insulins, it has been noted that higher doses and
twice-daily dosing are often required with DET compared
with GLA [3,4]. A recent trial has suggested that when both
DET and GLA are used once daily as an adjunct to metformin,
a greater proportion of patients treated with GLA reached
glycated haemoglobin (HbA1c) levels<7.0% than did patients
treated with DET [5].
Attempts to examine the relative advantages of these insulin
analogues in a real-world setting have proved difficult to
interpret. Some studies have reported enhanced glycaemic
control with GLA compared with DET, along with improved
adherence and persistence, with no difference with regard to
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hypoglycaemia, healthcare costs or weight gain [6–8]; however,
other studies found no difference in glycaemic control between
the two insulin types [9,11], with one suggesting that patients
initiating DET were 30% less likely to gain 0.9 kg or more in
body weight than GLA users [10]. Studies investigating the
efficacy and safety of switching from GLA to DET are similarly
conflicting in their findings. Although once-daily dosing of
GLA and DET has been shown to result in equivalent 24-h
glycaemic control, switching from GLA to DET was associ-
ated with improved HbA1c levels and fewer hypoglycaemic
events, compared with remaining on GLA in an observational
study of patients with type 1 diabetes mellitus (T1DM) and
T2DM [7,11,12]. A retrospective analysis, however, reported
that switching from GLA to DET did not improve glycaemic
control among a cohort of patients with T2DM [13].
A recent longitudinal study sought to expand on these data
by assessing real-world outcomes using a retrospective anal-
ysis of two large, independent, national, US databases com-
prising commercially insured and Medicare populations: the
IMPACT® andHumana® cohorts [14].The study found that, at
1-year follow-up, patients who had remained on GLA showed
significantly higher persistence with and adherence to treat-
ment comparedwith thosewho switched toDET (p< 0.001). In
addition, 37% of patients who switched to DET restarted GLA
(p< 0.05), compared with only 20% of GLA users returning
to DET after having switched to GLA. Overall hypoglycaemia
rates were significantly higher for patients continuing on GLA
than for patients switching to DET in the Humana cohort (16
vs. 11%; p< 0.05), but overall hypoglycaemia rates were similar
in the IMPACT cohort (11 vs. 12%; p= 0.490).
In the present study, to further evaluate the consequences of
insulin switching, we used data from patients’ medical records
to investigate retrospectively the real-world clinical outcomes
for patients with T2DMwho switched between these two basal
insulin analogues.
Methods
The present analysis was a retrospective cohort study using
the GE Centricity Electronic Medical Records (EMR) database
from1 July 2005 to 31December 2012. In 2007, theGECentric-
ity EMR database contained themedical records of∼30million
patients in 49 US states. As the analysis was performed on
de-indentified data, approval from an ethics committee was not
necessary.
Patients
Weanalysed two cohorts in the present study: cohort 1 included
patients who were previously treated with GLA and switched to
DET (DET-S) or who remained on GLA (GLA-C); and cohort
2 included patients previously treated with DET and subse-
quently switched to GLA (GLA-S) or who remained on DET
(DET-C). In cohort 1, the patients in the DET-S subgroup were
required to have≥1 physician prescription for GLA<6months
before first DET physician prescription order date (after 1 Jan-
uary 2006). The first DET physician prescription date was des-
ignated as the index date. Patients in the GLA-C subgroup were
required to have≥2 GLA physician prescriptions starting from
the third-quarter of 2005, without a subsequent physician pre-
scription order of DET, with≥1 of the orders being<6months
before the index date. The index date was a randomly selected
date between the second to the last GLA physician prescription.
In cohort 2, patients in the GLA-S subgroup were required to
have≥1 physician prescription for DET<6months before the
first GLA prescription order date (after 1 July 2006). The first
GLA physician prescription date was designated as the index
date. Patients in the DET-C subgroup were required to have≥2
DET physician prescriptions starting from the first-quarter of
2006, without a subsequent physician prescription order for
GLA.The index date was a randomly selected date between the
second and last DET physician prescriptions dates.
Patients aged ≥18 years on the index date were included in
the analysis if they had a diagnosis of T2DM [International
Classification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) codes: 250.x0 or 250.x2] with EMR activ-
ity data for≥6months pre-index (baseline) and 12months
post-index (follow-up). Patients were further required to have:
≥1 baseline HbA1c measure taken during the period 90 days
before up to 15 days after the index date;≥1 baseline bodymass
index (BMI) measure taken in the period 30 days before up
to 15 days after the index date; and≥1 follow-up HbA1c mea-
sure from the second-quarter until 3months after the 1-year
follow-up. In cohort 1, patients with baseline prescriptions for
premixed insulin or basal insulins other than GLA [i.e. neutral
protamine Hagedorn (NPH) insulin, Lente, or Ultralente] were
excluded. Similarly, in cohort 2, patients with baseline prescrip-
tions for premixed insulin or basal insulins other thanDET (i.e.
NPH insulin, Lente or Ultralente) were excluded.
Measures
Baseline demographic and clinical characteristics included age,
gender, region, race, geographic region, insurance type, BMI,
weight, individual comorbidities and prescribed diabetes med-
ications. In addition, the Charlson Comorbidity Index (CCI)
score was calculated, which is the weighted sum of 19 cat-
egories of comorbidity defined using ICD-9-CM diagnoses
codes, with a higher score indicating a more severe burden
of comorbidity and a higher mortality risk [15,16]. Clinical
outcome variables were measured 1 year after the index date
(follow-up) and included follow-up HbA1c, change in HbA1c
frombaseline, follow-uphypoglycaemic events, follow-upBMI,
change in BMI from baseline follow-up body weight, change in
bodyweight frombaseline and follow-up oral antidiabetes drug
(OAD) use (including GLA, DET and rapid-acting insulin).
Baseline HbA1c measures were defined as those occurring
between 90 days before and up to 15 days after the index date;
baseline body weight and BMI measures were defined as≥1
baselinemeasurement between 30 days before andup to 15 days
after the index date. Follow-up HbA1c values were defined as
those occurring during the period from the second-quarter
until 3months after 1-year follow-up, and follow-up body
weight and BMI values were defined as those occurring dur-
ing the 30 days before or after the end of the 1-year follow-up
period (index date+ 360 days). If patients hadmultiple HbA1c,
body weight or BMI results during this period, the value dated
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closest to the index date was used as the baseline value, and the
value dated closest to the end of the follow-up period was used
as the follow-up value.
Hypoglycaemia was defined as a healthcare encounter
(outpatient, inpatient or emergency department visit) with a
primary or secondary ICD-9-CM diagnosis code for hypogly-
caemia, based on the algorithm published by Ginde et al. [17].
Both the proportion of patients with≥1 hypoglycaemic event
(prevalence rate) and the average number of hypoglycaemic
events per patient (event rate) during the baseline and 1-year
follow-up period were identified.
Treatment persistence was defined as the patient remain-
ing on the index long-acting insulin (GLA for GLA-C and
DET for DET-S for cohort 1; DET for DET-C and GLA for
GLA-S for cohort 2) during the 1-year follow-up period with-
out discontinuation after study drug initiation. Based on the
published methodology [18], study medication was consid-
ered discontinued if the prescription was not re-ordered by the
physician within the expected time of medication coverage (the
pre-defined 90th percentile of the time between first and second
physician prescriptions among patients with≥1 prescription).
Patients who restarted their initial medication after a period
of not having used this medication during follow-up were con-
sidered non-persistent. Persistence days were measured as the
number of days between the index date and the discontinuation
date. Sensitivity analyses were also conducted using 75th and
95th percentiles of the expected time of medication coverage.
Data Analysis
Descriptive and multivariate statistical methodologies were
used to assess the baseline characteristics and to compare
the outcomes over the 1-year follow-up period. To address
potential selection bias in the real-world setting, in each
cohort, patients from the two subgroups were matched by
propensity-score matching, with a 1 up to 5 ratio in cohort 1
and a 1 up to 3 ratio in cohort 2, to balance baseline age, gender,
race, geographic region, insurance type, physician specialty,
index year, baseline comorbidity, baseline OAD use, concomi-
tant medication, HbA1c and BMI. These ratios and matchings
were chosen because our preliminary analysis revealed a pre-
scription imbalance, with significantly more eligible patients
in the GLA group when compared with the DET group, and a
much lower number of patients in the ‘switcher’ groups versus
the ‘continuer’ groups. Additionally, one-to-many matching
has previously been validated as a method to increase precision
in cohort studies, compared with one-to-one matching, and
has also been supported in a recent review assessing the quality
of statistical methodologies in matched case–control studies
[19,20]. Matching was implemented without replacement and
any patient without≥1 match was excluded from the analysis.
Between-group covariate balance was evaluated using descrip-
tive t-tests and chi-squared tests (with corresponding p-values)
and standardized differences, where a standardized difference
<10 indicated adequate balance [21].
Because not every patient in the matched cohorts had
follow-up BMI or body weight data, we conducted, as sen-
sitivity analysis, ordinary least squares regressions for BMI
and body weight changes, adjusting for potential baseline
imbalances. The model used a larger set of covariates, which
included patient demographics (age, gender, geographic loca-
tions and BMI categories), baseline comorbidities and some
basic clinical characteristics (baseline OAD use, statins for
baseline concomitant medication use, baseline HbA1c level
and baseline hypoglycaemic events).
Results
A total of 25 290 eligible patients were identified with 19 811
patients from cohort 1 (GLA-C, n= 17 783 and DET-S,
n= 2028) and 5479 from cohort 2 (DET-C, n= 4431 and
GLA-S, n= 1048). Patient attrition is shown in Figure 1. Sig-
nificant baseline differences existed between the subgroups
in each cohort (Table S1). In cohort 1, when compared with
patients in the DET-S subgroup, patients in the GLA-C sub-
group were older, were more likely to be black, were more
likely to reside in the Midwest or West, were more likely to be
enrolled in Medicare, had higher CCI scores and had lower
HbA1c values. No significant differences were found for BMI
or body weight between the GLA-C and DET-S subgroups
at baseline. In cohort 2, when compared with the DET-C
subgroup, patients in the GLA-S subgroup were younger, were
more likely to be black, were more likely to reside in the Mid-
west or West, had higher HbA1c values, and had higher body
weight and BMI values. Patients in the GLA-S and DET-C sub-
groups had similar CCI scores at baseline. For both cohorts, no
significant differences were found for baseline hypoglycaemic
events between groups.
After propensity-score matching, the final matched study
population included 13 942 patients overall, with 10 657
from cohort 1 (GLA-C, n= 8860 and DET-S, n= 1797;
female patients 54.7%, age 58.4 years, HbA1c level 8.7%,
BMI 35.1 kg/cm2, weight 99.3 kg) and 3285 patients from
cohort 2 (DET-C, n= 2427 and GLA-S, n= 858; female 53.5%,
age 58.3 years, HbA1c level 8.8%, BMI 35.4 kg/cm2, weight
100.7 kg). The baseline demographic and clinical characteris-
tics were balanced between treatment groups in each cohort
(Table 1).
Insulin Utilization
During 1-year follow-up, overall, switching from GLA to DET
resulted in lower persistence with treatment, whereas switch-
ing from DET to GLA resulted in higher persistence. Among
patients in cohort 1, those in the DET-S subgroup versus those
in theGLA-C subgroup had significantly lower persistencewith
treatment (52.4 vs. 61.3%, respectively; p< 0.0001) and signif-
icantly fewer treatment persistent days (311.6 vs. 331.0 days;
p< 0.0001). In cohort 2, however, the GLA-S and the DET-C
subgroups had similar levels of treatment persistence (56.5 vs.
58.5%, respectively; p= 0.292) yet fewer treatment persistent
days (320.7 vs. 325.3 days; p= 0.015).
Sensitivity analysis using 75th and 95th percentile of
the time duration yielded similar results: 75th percentile:
cohort 1 GLA-C versus DET-S subgroup, 21.2 versus 35.7%
(p< 0.0001); cohort 2 DET-C versus GLA-S subgroup, 24.7
versus 31.6% (p= 0.0001); 95th percentile: cohort 1 GLA-C
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Figure 1. Patient attrition. BMI, body mass index; EMR, electronic medical records; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus.
versus DET-S subgroup, 63.1 versus 68.2% (p< 0.0001);
cohort 2 DET-C versus GLA-S subgroup, 67.0 versus 66.0%
(p= 0.622).
In cohort 1, the use of rapid-acting insulin was signif-
icantly higher among the patients in the DET-S subgroup
than among those in the GLA-C subgroup (57.6 vs. 52.5%;
p< 0.0001; Figure 2), and 26.9% of patients in the DET-S sub-
group restarted GLA. In cohort 2, however, similar proportions
of patients used rapid-acting insulin in the DET-C and GLA-S
subgroups (50.4 vs. 51.1%; p= 0.712), and 18.6% of patients in
the GLA-S subgroup restarted DET.
Clinical Outcomes
The baseline mean HbA1c level was similar between the treat-
ment groups in each of the cohorts. In cohort 1, patients in the
DET-S subgroup had a significantly higher follow-up HbA1c
level (Figure 3A), a significantly lower HbA1c reduction
(Figure 3B), and significantly lower proportions of patients
achieved HbA1c <7.0% (Figure 3C) and HbA1c<8.0%
(Figure 3D) at the end of 1-year follow-up compared with
patients in the GLA-C subgroup. In cohort 2, however, com-
pared with patients in the DET-C subgroup, patients in the
GLA-S subgroup had a significantly lower follow-up HbA1c
(Figure 3A) and a numerically higher (although not statistically
significant) HbA1c reduction (Figure 3B), but there were no
differences in the proportions of patients achieving an HbA1c
level<7.0% (Figure 3C) or<8.0% (Figure 3D).
For both prevalence and event rates of any hypoglycaemic
events, no significant differences were found after follow-up
between the DET-S and GLA-C subgroups in cohort 1 or
between the GLA-S and DET-C subgroups in cohort 2 [preva-
lence rate: 2.0 vs. 2.1%, p= 0.889; event rate (number of
events/patient year): 0.023 vs. 0.026, p= 0.4424] or between
the GLA-C and DET-S subgroups in cohort 2 (2.3 vs. 1.6%,
p= 0.2314; event rate: 0.028 vs. 0.021, p= 0.3727).
In both cohorts, baseline BMI and body weight were sim-
ilar between the groups (Table 1). In cohort 1, BMI at 1-year
follow-up was 35.0 kg/m2 for both the DET-S and GLA-C
subgroups (p= 0.843). There were also no significant differ-
ences in BMI change for patients in the DET-S and GLA-C
subgroups after follow-up (Figure 4A). The 1-year follow-up
weight was similar for the DET-S and GLA-C subgroups (99.3
vs. 99.4 kg; p= 0.881), with similar weight changes between
patients in the DET-S subgroup and those in the GLA-C sub-
group (Figure 4B).
In cohort 2, at the end of 1-year follow-up, patients in
the GLA-S subgroup had a higher BMI (36.3 vs. 35.5 kg/m2;
p= 0.052), but this was not statistically significant. Change
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Table 1. Baseline characteristics among matched patients in cohorts 1 and 2.
Cohort 1 Cohort 2
DET-S GLA-C p GLA-S DET-C p
n= 1797 n= 8860 n= 858 n= 2427
Demographics
Women, n (%) 996 (55.4) 4831 (54.5) 0.4848 477 (55.6) 1281 (52.8) 0.1556
Mean (s.d.) age, years 58.1 (12.1) 58.4 (12.2) 0.2461 58.0 (12.5) 58.5 (11.9) 0.3701
Race, n (%) 0.9760 0.9802
White 967 (53.8) 4840 (54.6) 490 (57.1) 1383 (57.0)
Black 197 (11.0) 959 (10.8) 81 (9.4) 233 (9.6)
Hispanic 63 (3.5) 297 (3.4) 21 (2.5) 62 (2.6)
Other 47 (2.6) 222 (2.5) 23 (2.7) 56 (2.3)
Unknown/undetermined 523 (29.1) 2542 (28.7) 243 (28.3) 693 (28.6)
US region, n (%) 0.9293 0.9167
Midwest 414 (23.0) 1981 (22.4) 185 (21.6) 520 (21.4)
Northeast 495 (27.5) 2441 (27.6) 196 (22.8) 571 (23.5)
South 702 (39.1) 3502 (39.5) 383 (44.6) 1089 (44.9)
West 186 (10.4) 936 (10.6) 94 (11.0) 247 (10.2)
Insurance type, n (%) 0.9650 0.7944
Commercial 391 (21.8) 1859 (21.0) 171 (19.9) 521 (21.5)
Medicaid 51 (2.8) 254 (2.9) 12 (1.4) 38 (1.6)
Medicare 636 (35.4) 3155 (35.6) 312 (36.4) 859 (35.4)
Self-pay 31 (1.7) 150 (1.7) 23 (2.7) 53 (2.2)
Unknown 688 (38.3) 3442 (38.8) 340 (39.6) 956 (39.4)
Clinical characteristics
Mean (s.d.) HbA1c, % 8.7 (1.9) 8.7 (1.9) 0.4172 8.8 (1.8) 8.8 (1.9) 0.6951
HbA1c category, n (%) 0.0667 0.4926
<7.0% 283 (15.7) 1561 (17.6) 127 (14.8) 333 (13.7)
≥7.0 to <8.0% 457 (25.4) 2398 (27.1) 215 (25.1) 658 (27.1)
≥8.0 to <9.0% 403 (22.4) 1826 (20.6) 196 (22.8) 547 (22.5)
≥9.0 to <10.0% 282 (15.7) 1272 (14.4) 141 (16.4) 354 (14.6)
≥10.0% 372 (20.7) 1803 (20.3) 179 (20.9) 535 (22.0)
Mean (s.d.) BMI, kg/m2 35.1 (8.2) 35.0 (7.9) 0.5837 35.6 (8.0) 35.4 (7.8) 0.5149
Mean (s.d.) body weight, kg 99.5 (25.2) 99.3 (24.9) 0.7933 100.4 (24.8) 100.8 (25.1) 0.6780
Mean (s.d.) CCI score 1.13 (1.49) 1.11 (1.49) 0.5523 1.02 (1.45) 1.01 (1.37) 0.8216
Hypoglycaemia rates
Any hypoglycaemia, n (%) 24 (1.3) 92 (1.0) 0.2683 13 (1.5) 31 (1.3) 0.6024
Mean (s.d.) number of hypoglycaemic events per patient year 0.02 (0.14) 0.01 (0.12) 0.3674 0.02 (0.14) 0.01 (0.13) 0.7201
Comorbidities, n (%)
Hypertension 1385 (77.1) 6807 (76.8) 0.8227 658 (76.7) 1884 (77.6) 0.5729
Hyperlipidaemia 1429 (79.5) 7044 (79.5) 0.9862 697 (81.2) 1971 (81.2) 0.9876
Neuropathy 419 (23.3) 1959 (22.1) 0.2629 183 (21.3) 490 (20.2) 0.4773
Nephropathy 245 (13.6) 1096 (12.4) 0.1408 103 (12.0) 260 (10.7) 0.2995
Retinopathy 210 (11.7) 1020 (11.5) 0.8335 63 (7.3) 212 (8.7) 0.2056
Mental illness 841 (46.8) 4061 (45.8) 0.4542 376 (43.8) 1086 (44.7) 0.6398
Severe mental illness 183 (10.2) 918 (10.4) 0.8216 88 (10.3) 217 (8.9) 0.2538
OAD use, n (%)
Mean (s.d.) number of OADs 0.78 (0.92) 0.76 (0.91) 0.4920 0.89 (0.95) 0.85 (0.92) 0.3843
Metformin 627 (34.9) 3120 (35.2) 0.7938 347 (40.4) 981 (40.4) 0.9907
Sulfonylurea 377 (21.0) 1721 (19.4) 0.1306 192 (22.4) 546 (22.5) 0.9426
Thiazolidinedione 233 (13.0) 1072 (12.1) 0.3068 114 (13.3) 276 (11.4) 0.1361
Alpha-glucosidase 5 (0.3) 28 (0.3) 0.7927 3 (0.3) 5 (0.2) 0.4631
Dipeptidyl peptidase-4 inhibitor 127 (7.1) 661 (7.5) 0.5614 90 (10.5) 234 (9.6) 0.4740
Meglitinide 27 (1.5) 137 (1.5) 0.8907 15 (1.7) 33 (1.4) 0.4149
Glucagon-like peptide-1 analogue use, n (%) 90 (5.0) 454 (5.1) 0.8388 66 (7.7) 192 (7.9) 0.8378
Regular insulin use, n (%) 51 (2.8) 229 (2.6) 0.5403 16 (1.9) 28 (1.2) 0.1194
Rapid-acting insulin use, n (%) 716 (39.8) 3553 (40.1) 0.8391 313 (36.5) 876 (36.1) 0.8396
Other
Physician specialty, n (%) 0.8747 0.9534
Other 66 (3.7) 334 (3.8) 75 (8.7) 199 (8.2)
Endocrinology 136 (7.6) 624 (7.0) 51 (5.9) 139 (5.7)
Primary care 1092 (60.8) 5388 (60.8) 496 (57.8) 1421 (58.5)
Unknown specialty 503 (28.0) 2514 (28.4) 236 (27.5) 668 (27.5)
DET, insulin detemir; GLA, insulin glargine; DET-S, patients previously treated with GLA who switched to DET; GLA-C, patients who remained on
GLA; GLA-S, patients previously treated with DET who switched to GLA; DET-C, patients who remained on DET; BMI, body mass index; CCI, Charlson
Comorbidity Index; HbA1c, glycated haemoglobin; OAD, oral antidiabetes drug; s.d., standard deviation.
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Figure 2. Patients requiring rapid-acting insulin (RAI). DET, insulin
detemir; GLA, insulin glargine; DET-S, patients previously treated with
GLA who switched to DET; GLA-C, patients who remained on GLA;
GLA-S, patients previously treated with DET who switched to GLA;
DET-C, patients who remained on DET.
in BMI was significantly different (Figure 4A). There were
no significant differences at 1-year follow-up for body weight
between patients in theGLA-S andDET-C subgroups (102.2 vs.
100.9 kg; p= 0.299); however, patients in the GLA-S subgroup
had a greater change from baseline in body weight compared
with those in the DET-C subgroup (Figure 4B).
Sensitivity analyses using ordinary least squares regres-
sions yielded similar results: adjusted weight change: cohort
1 DET-S versus GLA-C subgroup, −0.18 versus +0.10 kg
(p= 0.329); cohort 2 GLA-S versus DET-C subgroup, +1.48
versus +0.02 kg (p< 0.001); adjusted BMI change: cohort
1 GLA-C versus DET-S subgroup, −0.18 versus −0.04 kg
(p= 0.122); cohort 2 GLA-S versus DET-C subgroup, +0.48
versus− 0.05 kg (p< 0.001).
Discussion
The aim of the present study was to evaluate retrospectively
the real-world clinical outcomes of switching between basal
insulin analogues, compared with continuing on previous basal
insulin, among patients with T2DM identified from the US GE
Centricity EMR database. Overall, contrasting findings were
observed when patients switched from GLA to DET, as com-
pared with switching from DET to GLA.
In cohort 1, compared with patients in the DET-S subgroup,
patients in the GLA-C subgroup had better clinical outcomes
at 1-year follow-up, including lower HbA1c levels and signifi-
cantly higherHbA1c reductions. In addition, significantlymore
patients in the GLA-C subgroup achieved the targeted HbA1c
levels of<7.0% or<8.0% and those in the DET-S subgroup had
significantly higher rapid-acting insulin use. In addition, no
significant differences in hypoglycaemia rates and weight/BMI
were observed between the two groups. These results could be
attributable to lower persistence/adherence as patients might
not be taking their full medication. In cohort 2, however,
patients in the GLA-S subgroup had lower HbA1c levels and
a numerically higher (but non-significant) HbA1c reduction;
Figure 3. (A) One-year follow-up glycated haemoglobin (HbA1c) values,
(B) change in HbA1c from baseline, (C) proportion of patients achiev-
ing target HbA1c<7.0%, and (D) proportion of patients achieving tar-
get HbA1c<8.0%. DET, insulin detemir; GLA, insulin glargine; DET-S,
patients previously treated with GLA who switched to DET; GLA-C,
patients who remained on GLA; GLA-S, patients previously treated with
DET who switched to GLA; DET-C, patients who remained on DET.
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Figure 4. Changes in (A) body mass index (BMI) and (B) body weight
at 1-year follow-up. DET, insulin detemir; GLA, insulin glargine; DET-S,
patients previously treated with GLA who switched to DET; GLA-C,
patients who remained on GLA; GLA-S, patients previously treated with
DET who switched to GLA; DET-C, patients who remained on DET.
similar proportions of patients achieved HbA1c levels of <7.0
or <8.0%, and similar hypoglycaemia rates were seen in the
two groups. Although 1-year follow-up body weight and BMI
were similar, patients in the DET-C subgroup had a decreased
BMI and a lower body weight increase, whereas patients in
the GLA-S subgroup had increased BMI and significantly
greater body weight increase. Although the patients in the
GLA-S subgroup gained weight, the increase was<1% which,
it is suggested, is not clinically relevant [22], and may reflect
differences in follow-up plasma glucose levels or other factors.
Furthermore, the increase in weight with GLA could be taken
to be a sign of better compliance. If a switch between insulin
analogues is of a ‘disruptive nature’, it will result in decreased
compliance. For example, if a regimen becomes more complex
(from once daily to twice daily, adding a rapid-acting insulin
etc.), it could lead to less of the typical weight gain associated
with insulin treatment.
In cohort 1, the patients in the DET-S subgroup, who
switched from GLA to DET, had lower persistence than
those who remained on GLA (robust in sensitivity analyses).
This could be attributable to the fact that most patients on
DET administer twice daily, whereas most patients on GLA
administer once daily [13,23]. Unfortunately, this informa-
tion is not captured in the GE Centricity EMR database. By
contrast, in cohort 2, data on patients in the GLA-S subgroup
switching from DET to GLA suggested similar overall per-
sistence with treatment. Approximately 27% of the patients
in the DET-S subgroup restarted GLA during the follow-up
period. Of patients in the GLA-S subgroup, however, only
19% restarted DET during the follow-up period. Although the
reasons for restarting the former insulin are not captured in
the GE Centricity EMR database, these findings are consis-
tent with a previous IMPACT and Humana database study
[14]. Unlike randomized controlled trials, where patients
are required to be ‘persistent’ with their therapy, real-world
patients and physicians do not follow a stringent protocol and,
therefore, any differences in patients’ persistence with their
insulin treatment can translate into differences in clinical and
economic outcomes [17].
Overall, contrasting outcomes were observed when patients
were switched from GLA to DET, when compared with
switching from DET to GLA. This raises questions about the
therapeutic interchangeability of these two basal analogue
insulins in clinical practice, although further studies are
required to confirm this non-interchangeability. The results of
the present GE Centricity EMR switching analysis, however,
were highly consistent with the previously performed claims
database analysis [14].
The present study has a number of strengths. The GE Cen-
tricity EMR database is a large and comprehensive source
of data to understand clinical practice and outcomes in
the real-world setting. This database contains rich clinical
information, such as HbA1c level, weight and BMI, that is
not available in insurance claim databases. Overall 25 000
patients were identified in this study, and almost 15 000 were
propensity-score-matched and analysed, including those
switching from DET to GLA and those switching from GLA to
DET during the same time period. In previous observational
studies on switching from GLA to DET [11,13,24], conflicting
results were shown with relatively low numbers of patients
included (30–1300 patients) and including either only patients
with T1DM, or a mixed group of patients with T1DM and
T2DM. Our previous study used administrative claims data
[14], and the results described in the present study not only
validate our previous findings with a different data source but
also strengthen them with additional data on weight. One
of the key limitations of the present study, however, is that
the EMR analysis was carried out on primary care physician
prescription data, rather than on claims databases. Prescription
orders do not necessarily mean that the prescriptions were
filled and taken as directed. In addition, certain data were not
available, including glucose levels, the duration of treatment
with the initial insulin, the duration of T2DM, and the reason
for switching insulin (e.g. insurance required switching to
other insulin). Although propensity-score matching was used
to balance the baseline data between treatment groups, the
differences between the groups were quite significant (Table S1)
and the potential residual confounding might therefore still be
present, particularly unobserved selection bias. In a real-world
setting, switching patients to another treatment regimen may
introduce confounding by indication, an important limita-
tion to observational studies reporting on patients changing
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their treatment regimens, including the study described here.
It is difficult to amend for this by analyses. Other potential
sources of bias and confounding include the range of time from
measurement of HbA1c to index date, differences in time for
follow-up HbA1c and follow-up BMI, and patient/physician
preference. In addition, the dose of insulin at the time of
switching was not available in the GE Centricity EMR database
and might have impacted on clinical outcomes, especially in
patients who had recently switched insulin analogues and had
not had the opportunity to titrate their dosage. Specifically, the
present study was designed to compare between patients who
switched to a different basal insulin and those who continued
on the previous basal insulin. In the case of comparing patients
in the DET-S with those in the GLA-C subgroup, patients in
the latter subgroup may already be fully titrated, while it takes
time for patients switching to DET to titrate. This may lead to
an overestimation of the benefits of GLA compared with DET,
representing a further limitation of this analysis. The same
limitation applies to the comparison of the GLA-S with the
DET-C subgroup. One approach to account for confounding by
indication is to compare patients in the GLA-S subgroup with
those in the DET-S subgroup directly; however, these patients
had different baseline doses of basal insulin, and based on a
real-world study among US patients initiating GLA or DET, it
may be that higher insulin doses were used in the DET-treated
patients [6]. It is not possible to establish causality from the
differences in outcomes, nor are the data necessarily represen-
tative of all patients with T2DM. Patients could drop out for
various reasons and thus selection may occur. In the present
study, more patients treated with DET than those treated with
GLA dropped out from the study population (56 vs. 35%) when
6-month baseline and 12-month follow-up were required. Sim-
ilarly, only 8% of patients on DET treatment compared with
40% on GLA, dropped out when being aged >18 years was
required (Figure 1). Sufficient data on HbA1c levels and BMI
were missing for half of the patients in this analysis, and this
lack of completeness should be considered as a major limita-
tion of EMR databases. When interpreting the findings of the
present study, it should be remembered that, because of its
limitations, the methodology usedmay have introduced bias or
affected the ‘real-world’ representativeness of the results. Addi-
tionally, because of the real-world nature of the present study,
patients did not have their HbA1c levels or BMI evaluated
regularly and thus were excluded if they did not have baseline
and/or follow-up HbA1c/BMI values. Overall, recognizing the
inherent limitations of real-world data analyses, the findings of
the present study alone should not be used to guide clinicians
in the decision to switch insulin, but the findings do merit
further investigation. Future studies should look more closely
at a number of other factors, including the dose, duration of
treatment, reasons for and cost-effectiveness of switching in
patients with T2DM. In addition, although previous studies
have suggested that in patients with T1DMDETwas associated
with a higher dose and more frequent twice-daily dosing than
GLA [13,24], large cohort comparative studies in patients with
T1DM should be conducted to confirm these findings.
In conclusion, the results of the present study suggest that
switching patients with T2DM fromGLA to DETmight lead to
decreases in treatment persistence alongside having a negative
effect on glycaemic outcomes. Maintaining patients on GLA
or switching from DET to GLA, however, might be beneficial,
although may result in minor weight gain. This suggests that
the two basal insulin analogues might not be therapeutically
interchangeable, and further studies are required to investigate
this hypothesis.
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